National Allergy Strategy (NAS)

Expert Advisory Group Allergy, National Allergy Strategy Group (NASG) leadership, NASG Operational,

Working Groups & Stakeholder Groups: Terms of Reference

Mission: Collaboration to identify key priority objectives for a 10-year National Allergy Strategy to influence and deliver changes that will improve the lived experiences and health and well-being of all who live with allergy across the UK.

Name	**NAS Expert Advisory Group Allergy (EAGA) Co-Chairs**
Purpose	• Chair the Expert Advisory Group Allergy meetings. • Facilitate EAGA meetings and discussions as required. • Strategic and operational oversight of the NAS. • The EAGA chairs will report back to relevant agencies after each meeting, highlighting any areas of concern with regards to allergy policy. • Consider all EAGA member contributions and sharing with the wider stakeholders involved in the NAS. • Make urgent decisions, as required, in consultation with representations from EAGA and National Allergy Strategy Group (NASG) Leadership. • Acknowledge when there are differences of opinion in the NAS development and assist in resolving disputes and reconciling. • Advocate on behalf of the NAS.
Representation	• One co-chair to represent the Department of Health & Social Care Long Term Conditions lead (DHSC LTC). • One co-chair to represent the Chair of the National Allergy Strategy Group (NASG). • Co-chairs are equal in status within the EAGA.
Conduct	• The EAGA Co-Chair positions are voluntary and time attending meetings is unpaid. Expenses relating to the roles will be funded. • EAGA Co-Chairs must: • declare all potential conflicts of interest. • must ensure confidentiality of NAS activities unless approval is given by the EAGA to share. • must not work for any commercial industry that may benefit from a NAS, e.g. Pharmaceutical.

	• must not be affiliated with any political party in a public manner. • must act in the best interests of the NAS at all times. • must not use contacts for their personal or organisational gain without prior disclosure or discussion. • Acknowledge that the intellectual property belongs to the NASG.
Authority	• EAGA Co-Chairs have an advisory role for the NAS as the EAGA is not a decision-making group.
Timeline	• Co-chairs, or any replacement for each representative, will hold these positions for a period of 6 years.

Name of Group	NAS Expert Advisory Group Allergy (EAGA)
Purpose & Objectives	• The EAGA will provide an oversight and steering function for the development and subsequent implementation of the National Allergy Strategy, to be developed and delivered by the NASG. • Identifying priority areas to DHSC, National Health Services across the UK, and others, relating to allergy that require policy change or development and advise on how to best achieve improved outcomes. • Actively support the growth and delivery of high-quality, comprehensive, and geographically more diverse specialist allergy services and improve allergy care at all levels of an integrated care system. • Ensuring diverse and collaborative views and voices of key stakeholders inform recommendations for policymakers. • Supporting the development of a new National Allergy Strategy, endorsing the final strategy and actively contributing to its implementation. • Providing an advisory function for the development of various policies aimed at improving the lives of people living with allergy. • Where appropriate, acting as advocates for the allergy community at a governmental level. • Maintain broader contact with the allergy community through patient advocacy groups/charities.
Representation from/including:	The Group will include a range of representatives from relevant influencing organisations. The membership of the Group is as follows: • Co-Chair: Chair of NASG Prof Adam Fox Co-Chair: DHSC Senior Policy Advisor Lee McGill • All-Party Parliamentary Group for Allergy: Chair – TBC • British Association of Dermatologists: President: Professor Tamara Griffiths • British Dietetic Association: Karen Wright and Justine Dempsey • British Paediatric Allergy, Immunology & Infectious Disease Group, representing the Royal College of Paediatrics & Child Health, Allergy Leads: Dr Rosy Wells & Dr Maeve Kelleher • British Psychological Society: Dr Rebecca Knibb • British Society for Allergy & Clinical Immunology: President Professor Graham Roberts • British Society for Cutaneous Allergy: Dr Graham Johnson • British Society for Immunology Clinical Immunology Professional Network (BSI-CIPN): Dr Sinisa Savic • Department for Education: School Food Unit/Families Group: Deputy Directors Kate Cropper, Heidi Holmes, Sachin Shah

	• Foods Standards Agency: Head of Policy & Strategy for Food Hypersensitivity: Sushma Acharya • Immunology and Allergy NHSE Clinical Reference Group: National Specialty Advisor & Chair: Dr Claire Bethune • Immunology, Infectious Disease and Allergy representative of the Specialist Paediatric Medicine NHSE Clinical Reference Group: Professor Saul Faust • Joint Clinical Immunology & Allergy Committee of the Royal College of Physicians & Royal College of Pathologists: Chair: Dr Patrick Yong • Medical Schools Council: Senior Policy officers: Rachel Rulton and Roisin McCallion • Medicines Health Regulatory Agency: Julian Beach • NHSE Blood & Infection National Programme of Care Board: Chair and National Clinical Director: Dr Siraj Misbah • NHSE Lead for workforce planning: TBC • Northern Ireland representative: TBC • Royal College of General Practice: Dr Liz Angier • Royal College of Nursing: James Gardner • Royal College of Paediatrics and Child Health Medical Specialities Board: Professor Nick Makwana • Royal College of Physicians: Improving Quality of Allergy Services Clinical Lead: Dr Nasreen Khan • Royal College of Physicians' Medical Specialties Board: Dr. Robin Gore • Royal Pharmaceutical Society: Mr Hadar Zaman • Scottish representative: CYANS Lead Clinician, Consultant Paediatrician: Dr Adrian Sie • UK Health Security Agency (UKHSA) Vaccinology Allergy Representative: Dr Paul Turner • UK Perioperative Allergy Network (representing BSACI, CIPN, Association of Anaesthetists, Royal College of Anaesthetists): Chair: Dr Louise Savic • Welsh representative: Consultant Immunologist: Dr Tariq El-Shanawany (Cardiff and Vale UHB - Immunology) • PATIENT AND CARER REPRESENTATIVES: • Allergy UK: Chief Executive Officer: Simone Miles • Anaphylaxis UK: Chief Executive Officer: Simon Williams • Natasha's Allergy Research Foundation: Chief Operations Officer: Alicia Kennedy (The Baroness Kennedy of Cradley)

Conduct	• The EAGA positions are voluntary and time attending meetings is unpaid. Expenses relating to the roles will be funded. • EAGA representatives must: • declare all potential conflicts of interest. • must not work for any commercial industry that may benefit from a NAS, e.g. Pharmaceutical. • must not be affiliated with any political party in a public manner. • must act in the best interests of the NAS at all times. • must not use contacts for their personal or organisational gain without prior disclosure or discussion. • Acknowledge that the intellectual property belongs to the NASG. • All discussions held by the EAGA are subject to the strictest confidentiality rules. If any member or participant wishes to share any part of the discussions or papers shared within EAGA, they must ask for permission from the chair.
Authority	• EAGA has a solely advisory function and is accountable to the DHSC and NASG.
Timeline	• EAGA will meet virtually 3 times per year in April, September, and December. • The Terms of Reference will be reviewed every year to ensure the group is working effectively to support the NASG in its development and implementation of the National Allergy Strategy. • Representation on the EAGA will be reviewed on-going to reflect NAS activities.
Standing Agenda Items	• Each meeting will include updates on the progress of the NAS. • Each meeting will include updates on policy areas which may impact on the NAS objectives. • Each meeting will include UK-wide consideration and information.
Inputs	• The group will also receive regular updates on progress in relation to the National Allergy Strategy, to allow for comments and other input into its development. • Representatives will update on policy or other changes in their area of expertise that relate to the NAS. • Representatives will provide best practice advice for NAS activities. • Representatives will share opportunities where it may be possible to raise awareness of the NAS.
Outputs	• The group will review the progress of the National Allergy Strategy and identify key priorities in relation to the holistic care of people with allergies. • It aims to reach consensus about the best means of improving allergy care and communicate this to the relevant agencies. • Minutes will be taken of all meeting discussions.

	• EAGA will produce an annual report, highlighting priorities for policy change and development. • EAGA chair(s) will hold an annual engagement event, at the annual conference of the BSACI, to highlight its' activities and findings over the year.
Secretariat	• Secretariat is provided by the BSACI on behalf of the NASG.

Name of Group	**National Allergy Strategy Group Leadership (NASGL)**
Purpose & Objectives	•NASGL has the strategic and operational oversight of the NAS, considering advice from the Expert Advisory Group for Allergy (EAGA). • NASGL oversees all contracts relating to the NAS, including sponsorship, grants, selection criteria and recruitment of posts and/or expressions of interest. •NASGL has ownership and accountability for the delivery of the NAS. • NASGL has responsibility for ensuring there are sufficient resources available to enable the NAS activities to be delivered. • NASGL provides administration and team support to assist the Project Manager with the NAS activities, including stakeholder communications, group meetings, consultations, event management, and reviewing of draft documents. • NASGL has ownership of the communication activities and public health campaign for NAS. • NASGL collectively advocates on behalf of the NAS. • NASGL supports the implementation of the NAS. • NASGL is responsible for organising the printing and publication of the NAS.
Representation	• NASG Core members, including: • British Society for Allergy & Clinical Immunology (BSACI) • Allergy UK • Anaphylaxis UK • Natasha's Allergy Research Foundation (NARF)
Conduct	• The NASGL positions are voluntary and considered a part of NASG activities. Time attending meetings is unpaid. Expenses relating to the roles will be funded. • NASGL representatives must:

	• declare all potential conflicts of interest. • must not work for any commercial industry that may benefit from a NAS, e.g. Pharmaceutical. • must not be affiliated with any political party in a public manner. • must act in the best interests of the NAS at all times. • must not use contacts for their personal or organisational gain without prior disclosure or discussion. • acknowledge that the intellectual property belongs to the NASG. • keep all discussions strictly confidential and obtain permission from EAGA Co-chairs before sharing any part of discussions or papers outside of the NASGL. • share knowledge of projects/activities that may provide input/influence/outputs for the achievement of the NAS.
Authority	• NASGL has the over-arching responsibility and accountability for the NAS and is the key decision-making group for the NAS. • NASGL considers advice from EAGA. • The Project Manager reports to the Chair of the NASGL. • The NASGL guides and supports the operational activities of the NAS. • NASGL is responsible for identifying and managing finances received for the NAS. • Approval of grant/sponsorship expenditure is delegated to the BSACI, with reporting at NASG meetings. • NASGL considers and oversees disputes and reconciliation with guidance from the EAGA Co-chairs, including where resource allocation may be challenging.
Timeline	• NASG meetings are held virtually or in person a minimum of 4 times per year. • Membership of NASG is reviewed on an application basis.
Standing Agenda Items	• Each NASG meeting will include updates, discussions, and decisions on NAS activities. • Each NASG meeting will include updates on activities/projects that may impact NAS objectives.
Inputs	• Project Manager will provide updates on NAS activities, including requests for support and decisions where required. • NASGL members will provide updates on areas that impact/influence the NAS. • NASGL members will discuss resource allocations to support the development of the NAS. • Financial updates will be provided on NAS funds.
Outputs	• Minutes will be taken of all NAS discussions, recording decisions. • Guidance and support will be provided as appropriate to enable the NAS to progress.

Secretariat	• Allergy UK (equivalent of 1 day per week)

Name of Group	**National Allergy Strategy Group Operational (NASGO)**
Purpose & Objectives	• NASGO coordinates the NAS operational development and NAS activities. • NASGO reports regular updates to the NASGL on progress, challenges, opportunities, cost requirements, and outputs. • NASGO communicates with and supports all stakeholder engagement with the NAS. • NASGO supports workshop chairs with the delivery of workshop activities and the collation of stakeholder inputs into activities, including minutes and survey/consultation data. • NASGO oversees and delivers meeting event(s) – virtual or in-person. • NASGO oversees the drafting of the NAS report for NASGL to approve.
Representation	• The NAS Project manager (part-time post) oversees the coordination of NASGO activities. • NASGO includes NASG and other required team members with expertise to support and deliver NAS activities. • NASGO includes chairs from each workshop. • NASGO includes the lead for the NAS public awareness campaign/communication working group. • NASGO includes communication and data expertise from NASG and wider stakeholders to support with coordinating feedback and reviewing the NAS draft strategy document.
Conduct	• The NASGO positions are voluntary and considered a part of NASG activities, other than where remuneration is approved by NASGL. Time attending meetings is unpaid. Expenses relating to the roles will be funded. • NASGO representatives, and/or their organisations must: • declare all potential conflicts of interest. • must not work for any commercial industry that may benefit from a NAS, e.g. Pharmaceutical. • must not be affiliated with any political party in a public manner. • must act in the best interests of the NAS at all times.

	• must not use contacts for their personal or organisational gain without prior disclosure or discussion. • acknowledge that the intellectual property belongs to the NASG. • keep all discussions strictly confidential and obtain permission from EAGA Co-chairs before sharing any part of discussions or papers outside of the NASGL. • share knowledge of projects/activities that may provide input/influence/outputs for the achievement of the NAS.
Authority	• NAS Project Manager reports to the Chair of the NASGL • NASGO reports to the National Allergy Strategy Group Leadership (NASGL). • NAS Project Manager leads the coordination of the NASGO activities, ensuring team member organisations are informed, aware, and involved in discussions about the roles needed to be provided for activity delivery to be achieved. • The NAS Project Manager reports any concerns, disputes, or opportunities to the Chair of the NASGL. • All financial expenses must be pre-approved by the BSACI who is delegated to oversee finance management by the NASGL.
Timeline	• NASGO will meet virtually once a month to over-view progress. • NAS Project Manager will meet with the NASGL Chair bi-weekly. • NASGO activity meetings will take place as needed to ensure that the NAS activities can move forward. • Representation of the NASGO will be reviewed on-going to reflect NAS activities.
Standing Agenda Items	• Monthly NASGO agenda items will relate to over-arching progress on activities, risks, challenges, and resource requirements. • Activity agenda items will be specific to each working group.
Inputs	• Core processes and procedures to be produced and monitored by NASGO. • Updates will be provided on NAS activities by relevant leads, including requests for support and decisions where required. • Financial expenditure requirements will be provided for NASGL approval. • Data, survey and consultation responses, and stakeholder feedback will feed into NASGO activities for collation, review, and processing to relevant working groups to review and decide.
Outputs	• Minutes will be taken of all NASGO discussions, recording decisions. • Guidance, support and relevant stakeholder data will be provided for all working groups as appropriate to enable the NAS activities to progress. • Regular communication to stakeholders.

	• Regular updates for NASGL and EAGA on progress.
Secretariat	• **TBC**

Name	**NAS Working Group Co-Chairs**
Purpose	• NAS Working Group Co-Chairs will have a role in the National Allergy Strategy Group Operational (NASGO) supporting the coordination and delivery of NAS activities. • NASGO will support workshop chairs with the delivery of workshop activities and the collation of UK-wide expert consultee inputs into activities, including minutes and survey/consultation data. • Co-chairs will oversee and guide Working Group activities and ensure outputs and outcomes are achieved, delegating to working group members who express interest in being involved. • Co-chairs will facilitate Working Group meetings and discussions as required and ensure all voices are heard. • Co-chairs can decide with working group members if they wish to consider sub-dividing activities into themed areas, to ensure all areas of allergy are included in the discussions and decisions. • Co-chairs will approve minutes taken of the working group activities by NASGO representatives. • Co-chairs will work with the NASGO to collate all stakeholder survey contributions into a draft set of key objectives and performance measures relating to working group areas. • Co-chairs will acknowledge when there are differences of opinion in the working groups and assist in resolving disputes and reconciling, discussing these with NASGL and EAGA Co-chairs where needed. • Co-chairs will present, share, and consult with other working groups at collaboration meetings. • Co-chairs will assist in identifying and engaging expert individuals and organisations ensuring all areas of allergy are included. • Co-chairs will support with communication channels, such as developing consultation surveys used to gather views and thematic analysis highlighting consensus on priorities.

	• Co-chairs will participate in drafting and reviewing the NAS working documents and consider consultation feedback to inform the final objectives for that theme. • Co-chairs will advocate on behalf of the NAS.
Representation	• Each working group will have two co-chairs providing a supportive approach to overseeing and guiding the working group activities. • Co-chairs will be appointed by the NASGL based on expressions of interest and relevant expertise and experience. • Co-chairs will need to have expertise in the area of the working group. • Co-chairs will need to have an understanding and knowledge of other issues and projects being undertaken in the area of the working group. • Co-chairs will need to be aware of stakeholders who may be interested in the working group and seek to ensure UK-wide voices are engaged.
Conduct	•The Working Co-Chair positions are voluntary and time attending meetings is unpaid. Expenses relating to the roles will be funded. •Working Group Co-Chairs must: •declare all potential conflicts of interest. •must ensure confidentiality of NAS activities unless approval is given by the EAGA. •must not work for any commercial industry that may benefit from a NAS, e.g. Pharmaceutical. •must not be affiliated with any political party in a public manner. •must act in the best interests of the NAS at all times. •must not use contacts for their personal or organisational gain without prior disclosure or discussion. •Acknowledge that the intellectual property belongs to the NASG. • Keep all discussions strictly confidential and obtain permission from NASGL before sharing any part of discussions or papers outside of the NAS activities. • Share knowledge of projects/activities that may provide input/influence/outputs for the achievement of the NAS.
Authority	• Working Group Co-chairs work with the NAS Project Manager and NASGO, which reports to the Chair of the NASGL. • Working Group Co-chairs guide the working groups and oversee the collation of expertise into key draft outputs and outcomes for the area of focus, ensuring these are comprehensive and inclusive of all areas of allergy. • Working Group Co-chairs sign off final drafts on specific working area activities for NASGL/EAGA comments and review.

	• Working Group Co-chairs discuss any concerns, disputes, or opportunities with the Project Manager and Chair of the NASGL. • All financial expenses must be pre-approved by the BSACI who is delegated to oversee finance management by the NASGL.
Timeline	• Co-chairs will hold the position until the NAS is published. • Working group activity meetings will take place as needed to ensure that the NAS activities can move forward. • Monthly update meetings will take place with the Project Manager, and Chair of NASGL.
Standing Agenda Items	• Monthly agenda items will relate to over-arching progress on activities, risks, challenges, and resource requirements. • Activity agenda items will be specific to each working group.
Secretariat	• NASGO will provide support for working group activities.

Name of Group	**NAS Working Groups**
Purpose & Objectives	• To bring together expert representatives into specific working groups and share subject matter expertise and knowledge of current policies, challenges, and systems relating to each NAS theme UK-wide, including all areas of allergy. • To collate evidence-based data on each theme that informs the current position/situation and gap analysis for each of the identified themes for the NAS. • To collaborate, propose, and develop solutions that inform over-arching short-, medium-, and long-term objectives relating to each theme. • Share knowledge of current key performance measures and monitoring systems. • Decide who, what, and how data could be monitored and measured for each objective considered in the working group. • Develop key performance indicators from these measures that could show outcomes over the NAS 2025-2035 timeframe for that themed area of priority. • Present, share, and consult with other expert working groups, where requested, and through other communication channels e.g. surveys used to gather views and thematic analysis highlighting consensus on priorities. • Participate in and review the NAS working documents and consider consultation feedback to inform the final objectives for that theme.

Representation	• Working groups will involve key experts in themed areas of: *Political Advocacy & Policy Advice;* • *Patient Pathways & Standards of Care* includes Anaphylaxis, Asthma and/or Rhinitis, Drug Allergy, Eczema, Food Allergy, Latex Allergy, Urticaria, Angioedema or Mastocytosis, and Venom Allergy. • *Clinical Workforce Education & Training in Allergy;* • *Early Years & Education – Managing the Allergy Healthcare Needs of Pupils;* • *Travel, Food Retail & Catering Industry – Safe Allergen Management Procedures;* • *Respiratory Health – Indoor & Outdoor Air Quality;* • *Evidence-based Allergy - Data, Metrics & Research Priorities;* • *Public Awareness Campaign – Communication Strategy for NAS.* • Patient representation must be in every themed working group. • Members of NASG can attend all working groups meetings, and they should indicate their intention to attend at the beginning of the process through the expression of interest process. • Working group members will need to have awareness and/or expertise in the area of the working group. • Working group members should share understanding and knowledge of other issues and projects being undertaken in the area of the working group. • Working Groups will aim to ensure UK-wide voices are engaged and heard so that there is UK-wide representation in NAS. • Working group members must be able to commit to the time and involvement required in activities to ensure the outputs and outcomes are achieved to inform the NAS. • Co-chairs can decide with working group members if they wish to consider sub-dividing activities into themed areas, to ensure all areas of allergy are included in the discussions and decisions.
Conduct	Involvement in the NAS Working Groups is voluntary and time attending meetings or supporting activities is unpaid. Expenses relating to the roles will be funded. •Working Group members must: •declare all potential conflicts of interest. •must ensure confidentiality of NAS activities unless approval is given by the NASGL. •must ensure that anyone working for a commercial industry does not seek to influence the NAS for the benefit of that industry. •must not be affiliated with any political party in a public manner. •must act in the best interests of the NAS at all times.

	•must not use contacts for their personal or organisational gain without prior disclosure or discussion. •Acknowledge that the intellectual property belongs to the NASG. • Keep all discussions strictly confidential and obtain permission from NASGL before sharing any part of discussions or papers outside of the NAS activities. • Share knowledge of projects/activities that may provide input/influence/outputs for the achievement of the NAS.
Authority	• Working Groups have an advisory role that provides expertise to inform the development of NAS objectives. • The working groups are not decision-making groups.
Timeline	• The current timeline is focused on the NAS being published in mid-late 2025. • Working group activity meetings will mainly take place virtually.
Inputs	• Subject matter expertise and knowledge shared on current policies, challenges, and systems relating to working group themes. • Evidence-based data will be collated to inform current and gap analysis on themed areas, for all areas of allergy • Collaboration to inform the development of solutions and prioritising these into short-, medium- and long-term objectives. • Share knowledge of current data and performance measurements and systems. • Collaborate to inform the development of NAS performance measures.
Outputs	• Short-, medium- and long-term objectives for working group theme areas will be proposed, for all areas of allergy. • Decisions on data monitoring and measurement for each objective will be developed. • Performance indicators for the working group theme areas to show NAS 2025-2035 outcomes. • A draft final set of objectives and performance measures for each themed working group.
Secretariat	• NASGO will provide support for working group activities.

Name of Group	NAS Stakeholder Terms of Reference
Purpose & Objectives	• Stakeholder involvement ensures that the NAS follows principles of informing, consulting, engaging, co-design, and co-production, listening to stakeholder ideas and opinions of those with lived and learned experience and expertise in allergy. • NAS wishes to be able to listen to all voices that wish to be heard and therefore there are various elements to stakeholder involvement including all stakeholders can be involved in surveys and other communication activities seeking feedback or comments, including the final consultation. • Specific stakeholders may be contacted with an invitation to express interest in participation and engagement with working groups. The NAS aims to be comprehensive and inclusive of all areas of allergy. • Stakeholders may wish to provide relevant evidence-based data on NAS working group areas of focus that inform the current position/situation and gap analysis, and working groups may contact these stakeholders to discuss this. • Stakeholders can share knowledge of current key performance measures and monitoring systems. • All stakeholders can participate in the review and consultation process to provide final comments for the final NAS draft. • All stakeholders can engage and support the public awareness campaign about the NAS once the NAS is published. • All stakeholders can support the implementation of the NAS objectives.
Representation	Representation across UK-wide stakeholders will ensure the involvement of voices that can inform the NAS working group objectives: • *Political Advocacy & Policy Advice;* • *Patient Pathways & Standards of Care* includes Anaphylaxis, Asthma and/or Rhinitis, Drug Allergy, Eczema, Food Allergy, Latex Allergy, Urticaria, Angioedema or Mastocytosis, and Venom Allergy. • *Clinical Workforce Education & Training in Allergy;*

	• *Early Years & Education – Managing the Allergy Healthcare Needs of Pupils;* • *Travel, Food Retail & Catering Industry – Safe Allergen Management Procedures;* • *Respiratory Health – Indoor & Outdoor Air Quality;* • *Evidence-based Data Metrics & Research Priorities;* • *Public Awareness Campaign – Communication Strategy for NAS.* These might include: • Policy advisors and civil servants advising UK-wide devolved governments. • Political influencing groups, such as All-Party Parliamentary Groups across various related topic areas. • Service providers and implementers in services related to NAS objectives, such as healthcare, schools, public health, pharmacy, academia, Royal Colleges, clinical service providers for all areas of allergy. • Patient voices, including those represented through patient organisations, lived experience, complaints feedback, Patient Reported Outcome Measures, and carers of those living with allergy. • Industry service providers in services related to NAS objectives, for example, Pharmaceutical medical treatment and equipment expertise and data, food industry, travel industry, urban planning and housing industry, and climate change. • Wider public representation. • Media and communication channels.
Conduct – Share Your Voice Survey	• Involvement as a stakeholder in completing the Share Your Voice survey is voluntary and unpaid. • Individuals completing the Share Your Voice survey do not need to complete a declaration of interest form. • Only comments submitted as a part of the survey will be accepted. • All comments will be collated and considered during the development of the strategy; however, whenever possible we encourage comments to be made through stakeholder organisations as it will not be possible to acknowledge and reply to every comment individually.
Conduct – Invited to be involved in a working group	Where a stakeholder representative is invited to be involved in a working group expenses relating to the roles will be funded. All stakeholders who participate in a working group activity must refer to the working group Terms of Reference, and must: • declare all potential conflicts of interest. • must ensure confidentiality of NAS activities unless approval is given by the NASGL. • must ensure that anyone working for a commercial entity does not seek to influence the NAS for commercial gain.

	• must not use any political party affiliation to influence their role in the NAS in a public manner. • must act in the best interests of the NAS at all times. • must not use contacts for their personal or organisational gain without prior disclosure or discussion. • Acknowledge that the intellectual property belongs to the NASG. • Keep all discussions strictly confidential and obtain permission from NASGL before sharing any part of discussions or papers outside of the NAS activities. • Share knowledge of projects/activities that may provide input/influence/outputs for the achievement of the NAS.
Authority	• Stakeholders will not be decision-makers, but their comments will be considered as a part of the working group discussions. • National Allergy Strategy Group reserves the right to summarise and edit comments received during consultations, or not to publish them at all if they are too long, inappropriate, or contain confidential information. • A summary of comments will be published on the National Allergy Strategy Group website for transparency and openness, but without endorsement by the National Allergy Strategy Group or any other party involved in the development of the UK National Allergy Strategy.
Timeline	• The Share Your Voice survey will be open for approximately 12 weeks from August 2024 to 15th November 2024 • The Expressions of Interest survey will be open for 7 weeks from August 2024 to the 7th of October 2024. • The current timeline is focused on a final consultation being circulated during mid-2025. • The current timeline is focused on the NAS being published in October 2025.